Linda Yaccarino, the former X CEO who left the social media company last month in the wake of yet another Elon Musk ...

Yaccarino, who has a house in Woodbury, graduated from Deer Park High in 1981 with her twin sister, Lori. Both were elected ...

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...

Despite not coming from a healthcare background, Yaccarino brings over a decade of experience in digital revenue and brand ...

Linda Yaccarino, the former CEO of Elon Musk 's social media platform X, has been appointed as the new CEO of eMed Population ...

Yaccarino will be CEO of a unit at the company, which focuses on patients taking weight-management and diabetes medications.

Yaccarino, an advertising industry veteran, exited Elon Musk's X after two turbulent years during which she tried to revive ...

Yaccarino has been named CEO of Miami-based eMed Population Health, which calls itself “the leading digital health platform ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...